PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

National Stepped-Care Rollout Lifts Buprenorphine Access for Homeless-Experienced Veterans

buprenorphinenaltrexonemethadonemedication for opioid use disorderopioid use disorderhomelessnessveteransstepped careSCOUTTimplementation sciencesynthetic difference-in-differencesentropy balancingopioid stewardshipretrospective cohort Behavioral Health / Addiction Medicine

Background Information

Stepped-care model boosts opioid disorder treatment among homeless veterans.

Expanding medication treatment for opioid use disorder (MOUD) among homeless veterans can enhance care accessibility and outcomes. MOUD receipt increased from 45.0% to 61.1% in SCOUTT facilities post-implementation, compared to non-SCOUTT facilities (41.9% to 49.7%). The study highlights the role of a stepped-care model to improve MOUD access, particularly buprenorphine, in non-specialty settings for homeless populations. National initiatives can enhance MOUD access in underserved populations, closing treatment gaps.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Li H, Baylis JD, Huebler S, Gordon AJ, Hawkins E, Hagedorn HJ, Kertesz SG, Suo Y, Zhang Y, Jones AL

Citation: Li H, Baylis JD, Huebler S, et al. Impact of a National Stepped-Care Model of Opioid Use Disorder Treatment on Access to Medication Therapies Among Homeless-Experienced Veterans. Health services research. 2026;61(5):e70171. doi:10.1111/1475-6773.70171

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.